Clinical Trial

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-21; most recent amendment 2025-12-04.
Status change: Not Yet Recruiting → Recruiting 2025-09-04
Trial Details
NCT Number NCT07145229
Lead Sponsor Atom Therapeutics Co., Ltd
Conditions Acute Gouty Arthritis, Gout Flare, Gout Flares, Acute Gout Flare
Enrollment 380 participants
Start Date 2025-08-26
Primary Completion 2026-05 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-08